Mendus AB (publ) (IMMU.ST)
SEK 4.95
(3.02%)
SEK 4.95
(3.02%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -101.61 Million SEK | 25.82% |
| 2022 | -136.99 Million SEK | -0.22% |
| 2021 | -136.69 Million SEK | -47.83% |
| 2020 | -92.46 Million SEK | 31.86% |
| 2019 | -135.7 Million SEK | -38.68% |
| 2018 | -97.86 Million SEK | -21.81% |
| 2017 | -80.33 Million SEK | -9.17% |
| 2016 | -73.58 Million SEK | -67.54% |
| 2015 | -43.92 Million SEK | -23.33% |
| 2014 | -35.61 Million SEK | -120.18% |
| 2013 | -16.17 Million SEK | -134.83% |
| 2012 | -6.88 Million SEK | -161.97% |
| 2011 | -2.62 Million SEK | 1.53% |
| 2010 | -2.67 Million SEK | -16.75% |
| 2009 | -2.28 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -35.61 Million SEK | 13.48% |
| 2024 Q2 | -38.24 Million SEK | -7.37% |
| 2023 Q3 | -26.4 Million SEK | -579.36% |
| 2023 Q4 | -41.16 Million SEK | -55.93% |
| 2023 Q2 | -3.88 Million SEK | 87.35% |
| 2023 FY | -101.61 Million SEK | 25.82% |
| 2023 Q1 | -30.72 Million SEK | 32.06% |
| 2022 Q2 | -29.28 Million SEK | -6.84% |
| 2022 Q3 | -39.8 Million SEK | -35.94% |
| 2022 FY | -136.99 Million SEK | -0.22% |
| 2022 Q4 | -45.23 Million SEK | -13.63% |
| 2022 Q1 | -27.4 Million SEK | 16.55% |
| 2021 Q2 | -32.13 Million SEK | 22.71% |
| 2021 Q1 | -41.57 Million SEK | -368.14% |
| 2021 FY | -136.69 Million SEK | -47.83% |
| 2021 Q4 | -32.84 Million SEK | -22.25% |
| 2021 Q3 | -26.86 Million SEK | 16.38% |
| 2020 Q3 | -22.24 Million SEK | 15.78% |
| 2020 Q1 | -31.71 Million SEK | 24.52% |
| 2020 FY | -92.46 Million SEK | 31.86% |
| 2020 Q4 | -8.88 Million SEK | 60.08% |
| 2020 Q2 | -26.41 Million SEK | 16.71% |
| 2019 Q4 | -42.01 Million SEK | -41.73% |
| 2019 Q1 | -29.14 Million SEK | -11.16% |
| 2019 Q2 | -33.22 Million SEK | -14.0% |
| 2019 Q3 | -29.64 Million SEK | 10.77% |
| 2019 FY | -135.7 Million SEK | -38.68% |
| 2018 Q2 | -19.35 Million SEK | 32.73% |
| 2018 FY | -97.86 Million SEK | -21.81% |
| 2018 Q1 | -28.77 Million SEK | -52.82% |
| 2018 Q4 | -26.21 Million SEK | -11.46% |
| 2018 Q3 | -23.52 Million SEK | -21.52% |
| 2017 Q3 | -21.65 Million SEK | -12.73% |
| 2017 Q1 | -20.63 Million SEK | 16.81% |
| 2017 FY | -80.33 Million SEK | -9.17% |
| 2017 Q4 | -18.82 Million SEK | 13.08% |
| 2017 Q2 | -19.21 Million SEK | 6.91% |
| 2016 Q1 | -9.61 Million SEK | 16.26% |
| 2016 FY | -73.58 Million SEK | -67.54% |
| 2016 Q4 | -24.8 Million SEK | -107.0% |
| 2016 Q3 | -11.98 Million SEK | 20.2% |
| 2016 Q2 | -15.01 Million SEK | -56.26% |
| 2015 Q4 | -11.47 Million SEK | -46.86% |
| 2015 Q1 | -10.61 Million SEK | 3.73% |
| 2015 Q2 | -7.8 Million SEK | 26.48% |
| 2015 Q3 | -7.81 Million SEK | -0.15% |
| 2015 FY | -43.92 Million SEK | -23.33% |
| 2014 Q1 | -5.01 Million SEK | -32.23% |
| 2014 FY | -35.61 Million SEK | -120.18% |
| 2014 Q4 | -11.02 Million SEK | -78.69% |
| 2014 Q3 | -6.17 Million SEK | -10.66% |
| 2014 Q2 | -5.57 Million SEK | -11.17% |
| 2013 Q3 | -1.78 Million SEK | 34.33% |
| 2013 FY | -16.17 Million SEK | -134.83% |
| 2013 Q2 | -2.72 Million SEK | -5.89% |
| 2013 Q1 | -2.57 Million SEK | -136.46% |
| 2013 Q4 | -3.79 Million SEK | -111.95% |
| 2012 Q4 | -1.08 Million SEK | 0.0% |
| 2012 Q3 | -1.08 Million SEK | 31.55% |
| 2012 Q2 | -1.59 Million SEK | 0.0% |
| 2012 Q1 | -1.59 Million SEK | 0.0% |
| 2012 FY | -6.88 Million SEK | -161.97% |
| 2011 FY | -2.62 Million SEK | 1.53% |
| 2010 FY | -2.67 Million SEK | -16.75% |
| 2009 FY | -2.28 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alzinova AB (publ) | -16.48 Million SEK | -516.62% |
| Amniotics AB (publ) | -30.87 Million SEK | -229.184% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -692.166% |
| BioArctic AB (publ) | 229.24 Million SEK | 144.327% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 78.202% |
| Genovis AB (publ.) | 61.5 Million SEK | 265.234% |
| LIDDS AB (publ) | -40.2 Million SEK | -152.746% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 935.065% |
| OncoZenge AB (publ) | -15.9 Million SEK | -539.033% |
| Saniona AB (publ) | -95.81 Million SEK | -6.063% |
| Simris Alg AB (publ) | -37.3 Million SEK | -172.4% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 67.319% |
| AcouSort AB (publ) | -17.08 Million SEK | -494.646% |
| Active Biotech AB (publ) | -45.8 Million SEK | -121.876% |
| Camurus AB (publ) | 431.44 Million SEK | 123.553% |
| Cantargia AB (publ) | -280.02 Million SEK | 63.711% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -381.812% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 10.328% |
| Kancera AB (publ) | -64.88 Million SEK | -56.604% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 1986.725% |
| Lipum AB (publ) | -37.17 Million SEK | -173.331% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -737.888% |
| NextCell Pharma AB | -41.95 Million SEK | -142.182% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 73.821% |
| Xintela AB (publ) | -54.08 Million SEK | -87.895% |
| Ziccum AB (publ) | -21.41 Million SEK | -374.589% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -519.704% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -467.799% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -174.12% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 43.44% |
| CombiGene AB (publ) | -35.66 Million SEK | -184.923% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 33.079% |
| Intervacc AB (publ) | -102.85 Million SEK | 1.199% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 59.121% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -23100.685% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -515.015% |
| Corline Biomedical AB | -1.8 Million SEK | -5517.413% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 42.859% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -78.841% |
| Aptahem AB (publ) | -11.11 Million SEK | -814.426% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 17.429% |
| Fluicell AB (publ) | -26.55 Million SEK | -282.688% |
| Biovica International AB (publ) | -124.82 Million SEK | 18.59% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -140.672% |
| Abliva AB (publ) | -95.5 Million SEK | -6.397% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 68.914% |
| 2cureX AB (publ) | -32.51 Million SEK | -212.501% |
| I-Tech AB | 20.2 Million SEK | 602.99% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 87.782% |
| Cyxone AB (publ) | -22.98 Million SEK | -342.033% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -11.179% |
| Biosergen AB | -27.03 Million SEK | -275.852% |
| Nanologica AB (publ) | -75.15 Million SEK | -35.209% |
| SynAct Pharma AB | -215.81 Million SEK | 52.913% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -130.669% |
| BioInvent International AB (publ) | -330.3 Million SEK | 69.235% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -328.104% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 59.207% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -923.353% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 7.017% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -770.175% |